gptkb:190070_(KRAS)
|
KRAS mutation analysis
|
gptkb:Durvalumab
|
gptkb:PACIFIC_trial
|
gptkb:RET_fusion-positive_cancers
|
LIBRETTO-001
|
gptkb:Remdesivir_(COVID-19_treatment)
|
gptkb:Solidarity_trial
|
gptkb:LYL797
|
Phase 1
|
gptkb:SAPIEN_3
|
gptkb:PARTNER_3
|
gptkb:Vaxzevria
|
Phase III
|
gptkb:EpiVacCorona_COVID-19_vaccine
|
Phase III (as of 2021)
|
gptkb:ESB-3
|
Phase 1
|
gptkb:HFE_gene
|
yes
|
gptkb:Corcept_Therapeutics
|
psychiatric disorders
|
gptkb:17-DMAG
|
investigational
|
gptkb:sintilimab
|
Phase III
|
gptkb:SRF114
|
Phase 1
|
gptkb:ACY-1215_(ricolinostat)
|
Phase 2
|
gptkb:SURPASS-4
|
Phase 3
|
gptkb:TCR-engineered_T_cell_therapy
|
Phase II
|
gptkb:VWF
|
ristocetin cofactor activity
|
gptkb:Palforzia
|
gptkb:ARTEMIS
|
gptkb:HER2/neu
|
immunohistochemistry
|